QuidelOrtho develops and sells in vitro diagnostic products for point-of-care settings, clinical laboratories, and transfusion medicine. Formed by the combination of Quidel and Ortho Clinical Diagnostics, it spans rapid immunoassays, molecular tests, clinical chemistry, and blood typing and screening systems. Its instruments and assays are used by hospitals, labs, physician offices, and blood banks to diagnose infectious disease, monitor health conditions, and ensure safe transfusions. The company competes on a broad menu of tests and an installed base of diagnostic platforms.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 613.9 | — | -255.4 | — |
| Q3 2025 | 699.9 | — | -733 | — |
| Q4 2025 | 723.6 | — | -130.7 | — |
| Q1 2026 | 619.8 | — | -91.8 | — |
| Q2 2026 | 630.9 | 2.8% | -92.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: American Bitcoin Corp (ABTC), NANO Nuclear Energy Inc. (NNE), Aebi Schmidt Holding AG (AEBI), NB Bancorp, Inc. (NBBK), Astec Industries, Inc. (ASTE), Ardelyx, Inc. (ARDX)